MX2023000948A - Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10). - Google Patents

Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).

Info

Publication number
MX2023000948A
MX2023000948A MX2023000948A MX2023000948A MX2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A MX 2023000948 A MX2023000948 A MX 2023000948A
Authority
MX
Mexico
Prior art keywords
cytokine fusion
cytokine
dual
fusion proteins
disorders
Prior art date
Application number
MX2023000948A
Other languages
English (en)
Spanish (es)
Inventor
John Mumm
Original Assignee
Deka Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deka Biosciences Inc filed Critical Deka Biosciences Inc
Publication of MX2023000948A publication Critical patent/MX2023000948A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • AIDS & HIV (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2023000948A 2020-07-20 2020-12-02 Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10). MX2023000948A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063054208P 2020-07-20 2020-07-20
PCT/US2020/062907 WO2022019945A1 (en) 2020-07-20 2020-12-02 Dual cytokine fusion proteins comprising il-10

Publications (1)

Publication Number Publication Date
MX2023000948A true MX2023000948A (es) 2023-04-14

Family

ID=79291996

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000948A MX2023000948A (es) 2020-07-20 2020-12-02 Proteínas de fusión de citocina doble que comprenden interleucina-10 (il-10).

Country Status (11)

Country Link
US (19) US11292822B2 (cg-RX-API-DMAC7.html)
EP (1) EP4181957A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023534847A (cg-RX-API-DMAC7.html)
KR (1) KR20230096959A (cg-RX-API-DMAC7.html)
CN (1) CN116322785A (cg-RX-API-DMAC7.html)
AU (1) AU2020459746A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023001187A2 (cg-RX-API-DMAC7.html)
CA (1) CA3186753A1 (cg-RX-API-DMAC7.html)
IL (1) IL300062A (cg-RX-API-DMAC7.html)
MX (1) MX2023000948A (cg-RX-API-DMAC7.html)
WO (1) WO2022019945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7641912B2 (ja) 2019-04-19 2025-03-07 シナーキン・ファーマ・ベスローテン・フエンノートシャップ Il13を含む融合タンパク質
CN116322785A (zh) * 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白
JP2024546999A (ja) * 2021-12-16 2024-12-26 デカ バイオサイエンシーズ, インコーポレイテッド Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー
AU2023225954A1 (en) * 2022-02-22 2024-09-05 Deka Biosciences, Inc. Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins
IL328577A (en) * 2023-11-24 2026-07-01 Medpacto Inc Fusion protein that specifically binds to extradomain b of fibronectin (edb-fn) and transforming growth factor beta (tgfβ) and its use
CN122555725A (zh) * 2024-01-08 2026-08-11 上药生物治疗(香港)有限公司 膜表达il-10及其用途
CN119954974B (zh) * 2025-04-09 2025-07-22 四川康德赛医疗科技有限公司 一种工程化巨噬细胞,其制备方法及抗纤维化的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989867A (en) 1996-09-23 1999-11-23 Knappe; Andrea DNA encoding IL-10-like homologue; related reagents
WO2001010912A1 (en) * 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
WO2004021861A2 (en) * 2002-09-03 2004-03-18 Vit Lauermann Targeted release
JP2009536170A (ja) 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
ES2536772T3 (es) 2007-09-21 2015-05-28 The Regents Of The University Of California El interferón dirigido demuestra potentes actividades apoptóticas y antitumorales
EP2209805B1 (en) 2007-10-30 2017-09-06 Philogen S.p.A. An antigen associated with rheumatoid arthritis
AU2009298131B2 (en) 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
JP2013534813A (ja) * 2010-05-26 2013-09-09 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗cd133抗体一本鎖可変断片、及びこれらの使用
WO2012045334A1 (en) 2010-10-05 2012-04-12 Synthon Bv Biologically active il-10 fusion proteins
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2872964T3 (es) 2011-07-27 2021-11-03 Philogen Spa Inmunoconjugado de IL-12
CN104245719B (zh) 2011-12-12 2016-09-14 宾夕法尼亚大学托管会 包含改进的il-12基因构建体的组合物和疫苗、免疫治疗剂及其使用方法
US20150038678A1 (en) 2012-02-29 2015-02-05 Ambrx, Inc. Interleukin-10 Polypeptide Conjugates and Their Uses
US9346872B2 (en) * 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
EP2903629B1 (en) * 2012-10-03 2019-07-10 Philogen S.p.A. Antibody conjugate for use in treating inflammatory bowel disease
WO2014153056A2 (en) 2013-03-14 2014-09-25 Parkash Gill Cancer treatment using antibodies that bing cell surface grp78
JP2016519111A (ja) 2013-04-26 2016-06-30 フィロゲン エスピーエー 細胞外マトリックス成分に対する抗体にコンジュゲートしたil4
BR112016016658A2 (pt) 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
IL300029A (en) 2014-05-16 2023-03-01 Baylor Res Institute Methods and preparations for the treatment of autoimmune and inflammatory conditions
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP3233920B1 (en) 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
WO2016191587A1 (en) 2015-05-28 2016-12-01 Armo Biosciences, Inc. Pegylated interleukin-10 for use in treating cancer
KR101811050B1 (ko) 2015-09-02 2017-12-21 경북대학교 산학협력단 항염증성 폴리펩티드와 페리틴 모노머 단편이 접합된 융합폴리펩티드 및 이를 유효성분으로 포함하는 염증성 질환 예방 및 치료용 약학적 조성물
WO2017091611A1 (en) 2015-11-23 2017-06-01 Immungene, Inc Enhanced cancer immunotherapy using antibody-interferon fusion molecules
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
WO2017178562A1 (en) 2016-04-12 2017-10-19 Philogen S.P.A. Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018156791A1 (en) 2017-02-22 2018-08-30 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
WO2018213335A1 (en) * 2017-05-16 2018-11-22 Scalmibio, Inc. Activatable antibodies and methods of use thereof
WO2019201866A1 (en) * 2018-04-16 2019-10-24 Swedish Orphan Biovitrum Ab (Publ) Fusion protein
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
CN114072164A (zh) * 2019-03-06 2022-02-18 德卡生物科学公司 Il-10变体分子和治疗炎性疾病和肿瘤的方法
EP4087947A4 (en) * 2020-01-09 2024-05-01 Deka Biosciences, Inc. METHODS OF USING GENETIC MARKERS, SNPS AND/OR INDELS TO DETERMINE SENSITIVITY TO IL-10 TREATMENT
CN115867275A (zh) 2020-04-13 2023-03-28 大学健康网络 治疗细胞因子释放综合征的方法
CN116322785A (zh) 2020-07-20 2023-06-23 德卡生物科学公司 包含il-10的双细胞因子融合蛋白
KR20240007204A (ko) 2021-05-11 2024-01-16 싱가포르 헬스 서비시즈 피티이 엘티디 키메라 항원 수용체 및 이를 포함하는 변형된 세포
KR20240156653A (ko) 2021-12-13 2024-10-30 데카 바이오사이언시즈, 인크. 다중-서브유닛 시토카인을 포함하는 이중 시토카인 융합 단백질
JP2024546999A (ja) 2021-12-16 2024-12-26 デカ バイオサイエンシーズ, インコーポレイテッド Il-10を含む二重サイトカイン融合物およびがんを処置するための養子細胞療法または二重特異性t細胞エンゲージャー
AU2023225954A1 (en) 2022-02-22 2024-09-05 Deka Biosciences, Inc. Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins

Also Published As

Publication number Publication date
US20220380428A1 (en) 2022-12-01
US12145007B2 (en) 2024-11-19
US12122814B2 (en) 2024-10-22
US20240076336A1 (en) 2024-03-07
CN116322785A (zh) 2023-06-23
BR112023001187A2 (pt) 2023-04-04
US11608368B2 (en) 2023-03-21
US20240059748A1 (en) 2024-02-22
US12110317B2 (en) 2024-10-08
US20240067687A1 (en) 2024-02-29
US20240059749A1 (en) 2024-02-22
US12263358B2 (en) 2025-04-01
US20250135241A1 (en) 2025-05-01
US11613563B2 (en) 2023-03-28
US20220017587A1 (en) 2022-01-20
US11572397B2 (en) 2023-02-07
US20220275040A1 (en) 2022-09-01
US20220281935A1 (en) 2022-09-08
EP4181957A1 (en) 2023-05-24
US20240059750A1 (en) 2024-02-22
IL300062A (en) 2023-03-01
US12116393B2 (en) 2024-10-15
US20240076339A1 (en) 2024-03-07
KR20230096959A (ko) 2023-06-30
US20240076337A1 (en) 2024-03-07
EP4181957A4 (en) 2024-08-07
US12116391B2 (en) 2024-10-15
US11292822B2 (en) 2022-04-05
WO2022019945A1 (en) 2022-01-27
US12116392B2 (en) 2024-10-15
AU2020459746A1 (en) 2023-03-16
US20240067688A1 (en) 2024-02-29
US20240076335A1 (en) 2024-03-07
US20240076338A1 (en) 2024-03-07
US12006346B2 (en) 2024-06-11
US12116390B2 (en) 2024-10-15
US20220275039A1 (en) 2022-09-01
US12121755B2 (en) 2024-10-22
US12268903B2 (en) 2025-04-08
US20220267397A1 (en) 2022-08-25
US20220340631A1 (en) 2022-10-27
CA3186753A1 (en) 2022-01-27
JP2023534847A (ja) 2023-08-14
US20220380427A1 (en) 2022-12-01
US11629178B2 (en) 2023-04-18
US11618775B2 (en) 2023-04-04
US12116389B2 (en) 2024-10-15

Similar Documents

Publication Publication Date Title
MX2024007270A (es) Proteinas de fusion de citocinas duales que comprenden citocinas de multiples subunidades.
BR112023001187A2 (pt) Proteínas de fusão de citocina dupla compreendendo il -10
EA201992765A1 (ru) Белки на основе антител с привитым цитокином и способы их применения в лечении рака
WO2023115033A3 (en) Dual cytokine fusions comprising il-10 and adoptive cell therapies or bispecific t-cell engagers to treat cancer
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
AU2015255979B2 (en) Using B-cell-targeting antigen IgG fusion as tolerogenic protein therapy for treating adverse immune responses
MY208638A (en) Anti-steap1 antigen-binding protein
PH12023552763A1 (en) Agonistic anti-il-2r antibodies and methods of use
MX2023001556A (es) Anticuerpos que se dirigen a egfr y uso de los mismos.
EP4623992A3 (en) Antibodies specifically binding to human il-1r7
RU2018106876A (ru) Новая комбинация для применения при лечении злокачественного новообразования
FI3978522T3 (fi) Humaaneja vasta-aineita Fel d1:lle ja niiden käyttömenetelmiä
EA202092162A1 (ru) Антитела против cxcl13 для лечения аутоиммунных заболеваний и рака
UA130540C2 (uk) Композиція антитіла b7-h4
BR112023016574A2 (pt) Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão
JOP20220070A1 (ar) مترافقات جسم مضاد- عقار مضاد لميزوثيلين إيريبولين وطرق استخدامها
MX2022005850A (es) Inmunoglobulinas modificadas para seleccionar depositos de amiloide como objetivo.
WO2021076554A8 (en) Antibodies targeting flt3 and use thereof
EP4610275A3 (en) Anti-pd-1 antibodies and fusion proteins
WO2022038417A3 (en) Modified il-18 polypeptides and uses thereof
EA201890805A1 (ru) Биспецифические антитела против cd3*cd19
MX2025002112A (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
WO2021226163A3 (en) Antibodies targeting clec12a and use thereof
MX2023002106A (es) Anticuerpos fgfr3 y metodos de uso.
WO2021231741A3 (en) Anti-pd-l1 antibodies and anti-pd-l1/il10 fusion proteins